Recommendations on prophylaxis for infective endocarditis: Dramatic changes over the past seven years  by Delahaye, François et al.
Archives of Cardiovascular Disease (2009) 102, 233—245
REVIEW
Recommendations on prophylaxis for infective
endocarditis: Dramatic changes over
the past seven years
Recommandations sur la prévention de l’endocardite infectieuse : une
évolution majeure an cours des sept dernières années
Franc¸ois Delahaye ∗, Brahim Harbaoui,
Virginie Cart-Regal, Guy de Gevigney
Hospices civils de Lyon, Claude-Bernard Lyon-I University, Lyon, France
Received 2 December 2008; received in revised form 7 January 2009; accepted 8 January 2009
Available online 19 March 2009
KEYWORDS
Infective
endocarditis;
Prophylaxis
Summary Recommendations on antibiotic prophylaxis against infective endocarditis have
changed dramatically since 2002. In 2002, the French were the ﬁrst to make a profound change:
they proposed that antibiotic prophylaxis should be optional when a medical, surgical or dental
procedure that carries a risk of infective endocarditis was performed in a patient at risk but
not at very high risk of infective endocarditis (group B: native valve disease, non-cyanotic con-
genital heart disease, obstructive hypertrophic cardiomyopathy). In 2004, the European Society
of Cardiology and the British Society of Cardiology made almost no changes to their previous
recommendations. In 2006, the British Society for Antimicrobial Chemotherapy made another
radical change: no antibiotic prophylaxis in group B patients. In 2007, the American Heart Asso-
ciation went a step further: no antibiotic prophylaxis before a gastrointestinal or genitourinary
procedure in group A patients (valvular prosthesis, cyanotic congenital heart disease, history of
infective endocarditis). In 2008, the British National Institute for Health and Clinical Excellence
adopted an extreme position: no antibiotic prophylaxis at all in patients at risk for infective
endocarditis.
© 2009 Elsevier Masson SAS. All rights reserved.
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MOTS CLÉS
Endocardite
infectieuse ;
Prophylaxie
National institute for health and clinical excellence (Nice), au Royaume-Uni, adopte la posi-
tion extrême de l’absence de toute antibioprophylaxie avant un geste à risque d’endocardite
infectieuse chez un cardiaque à risque d’endocardite infectieuse.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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that can induce IE is more likely to be caused by a daily
crossing of bacteria from mouth to blood than by occa-
sional buccodental care;
Table 1 Heart diseases with infective endocarditis risk;
French recommendations [3].
Group A: high-risk
heart diseases
Group B: lesser-risk heart
diseases
Valvular prostheses
Non-operated
cyanotic CHD and
surgical bypass
(pulmonary-
systemic)
History of infective
endocarditis
Valvular diseases: aortic
regurgitation, mitral
regurgitation, aortic stenosis
Mitral valve prolapse with
mitral regurgitation and/or
valvular thickening
Bicuspid aortic valve
Non-cyanotic CHD, except
atrial septal defect
Obstructive hypertrophicbbreviations
HA American Heart Association
CC American College of Cardiology
SAC British Society for Antimicrobial Chemotherapy
CS British Cardiac Society
HD Congenital heart disease
SC European Society of Cardiology
E Infective endocarditis
ICE British National Institute for Health and Clinical
Excellence
ackground
espite large improvements in the diagnosis and treat-
ent of infective endocarditis (IE), this disease remains
evere: the inhospital mortality rate is about 20%, the 5-
ear mortality rate is approximately 40%, and more than
0% of patients have to be operated on during the initial
hase [1]. While recommendations on prophylaxis against
E have existed for more than 50 years [2], they have
hanged dramatically over the past few years. In 2002,
he French were the ﬁrst to make drastic modiﬁcations
3—6]. In 2004, the European Society of Cardiology (ESC)
7] and the British Cardiac Society (BCS) [8] made virtu-
lly no changes to their existing recommendations, whereas
he British Society for Antimicrobial Chemotherapy (BSAC)
ssued recommendations in 2006 that were similar to the
rench recommendations [9]. In 2007, the recommenda-
ions of the American Heart Association (AHA) took the
ame direction [10]. In 2008, the recommendations by the
ritish National Institute for Health and Clinical Excellence
NICE) went even further [11]. This paper aims to review
he evolution of the recommendations over the past few
ears and the reasons behind the changes that have been
ade.002: major change to French
ecommendations
n 2002, the group that organized the consensus conference
n prophylaxis against IE in 1992 decided to review the liter-
ture published in the intervening 10 years and to consider
he opportunity for making a change to the recommenda-
ions. Three papers were issued: an argument that included
thorough review of the literature, and a ‘long version’ and
‘short version’ of the recommendations [3—5]. The recom-
endations were also published in the archives des maladies
u cœur et des vaisseaux [6] and an English version also
xists [12]. The following points were made:
IE remains a severe disease; in the mouth, bacteraemiaF. Delahaye et al.
Résumé Les recommandations sur la prophylaxie de l’endocardite infectieuse ont beaucoup
changé depuis 2002. Lors de la révision des recommandations de 1992, les Franc¸ais furent les
premiers, en 2002, à apporter un changement important, en proposant que l’antibioprophylaxie
soit optionnelle lors d’un geste à risque d’endocardite infectieuse chez les patients à risque mais
pas à très haut risque d’endocardite infectieuse (groupe B : valvulopathie native, cardiopathie
congénitale non cyanogène, cardiomyopathie hypertrophique obstructive). Alors que, en 2004,
la Société européenne de cardiologie et la Société britannique de cardiologie ne modiﬁaient
pas radicalement leurs recommandations précédentes, la Société britannique de chimiothérapie
antimicrobienne, en 2006, a maintenu l’antibioprophylaxie pour les patients à très haut risque
(groupe A : prothèse valvulaire, antécédent d’endocardite infectieuse, cardiopathie congéni-
tale cyanogène) mais pas pour les patients du groupe B. Les recommandations de l’American
heart association, en 2007, vont plus loin encore : pas d’antibioprophylaxie en cas de geste sur
les systèmes gastro-intestinal et génito-urinaire, quelle que soit la cardiopathie. En 2008, lecardiomyopathy (with murmur
at auscultation)
CHD: congenital heart disease.
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Table 2 Buccodental procedures; French recommendations [3].
Procedure Group A Group B
Intraligamentous local anaesthesia Contraindicated Contraindicated
Endodontic care: treatment of teeth with
devitalized pulp, including further surgical
pulp canal treatment
Contraindicated Contraindicated
Radicular amputation Contraindicated Contraindicated
Transplantation/reimplantation Contraindicated Contraindicated
Periapical surgery Contraindicated Contraindicated
Periodontal surgery Contraindicated Contraindicated
Implant surgery Contraindicated Contraindicated
Inserting ﬁlling material Contraindicated Contraindicated
Dentofacial orthopaedics Contraindicated Contraindicated
Preorthodontal surgery of impacted teeth Contraindicated Contraindicated
Antibiotic prophylaxis
Setting up a sterile operating area Recommended Optional
Non-surgical periodontal care
Scaling with or without polishing Recommended Optional
Probing Recommended Optional
Endodontic care: treating teeth with living pulpa Recommended Optional
Prosthetic procedures with a risk of bleeding Recommended Optional
Surgical procedures
Dental avulsion Recommended Optional
Healthy tooth Recommended Optional
Alveolectomy Recommended Optional
Separation of rootsb Recommended Optional
Impacted tooth or disimpaction Recommended Optional
Germectomy Recommended Optional
Frenectomy Recommended Optional
Biopsy of accessory salivary glands Recommended Optional
Bone surgery Recommended Optional
Dentofacial orthopaedics Recommended Optional
Inserting braces Recommended Optional
Non-invasive buccodental procedure (without important risk of bleeding)
Preventive procedures
Application of ﬂuor Not recommended Not recommended
Coronal sealing Not recommended Not recommended
Conservative procedures (coronal restoration) Not recommended Not recommended
Non-bleeding prosthetic procedures (impression) Not recommended Not recommended
Postoperative removal of sutures Not recommended Not recommended
Inserting removable orthodontic prostheses Not recommended Not recommended
Inserting or adjusting orthodontic devices Not recommended Not recommended
Dental X-rays Not recommended Not recommended
Non-intraligamentous local anaesthesia Not recommended Not recommended
In case of infection Antibiotic prophylaxis: non-adapted
Mandatory curative antibiotic therapy
a Endodontic care in groupA patients must be exceptional and can be undertaken only after checking the tooth’s vitality with adequate
tests, using a sterile operating area, in a single session, making sure that the entire pulp canal is accessible. This treatment must,
therefore, be reserved for monoradicular teeth, and perhaps for the ﬁrst premolar tooth if both pulp canals are accessible.
onlyb Separating roots should be avoided, if possible, and performed• there is no scientiﬁc proof of the efﬁcacy or inefﬁcacy of
antibiotic prophylaxis;
• in France, antibiotic prophylaxis before buccodental care
is performed in fewer than 50% of patients with at risk
heart disease;
•
•in the absence of any periodontal damage.even if the efﬁcacy of antibiotic prophylaxis was 100%,
widespread use would prevent only a very small number
of cases of IE;
in France, there is a worrying increase in bacteria that
are not completely sensitive to antibiotics.
2 F. Delahaye et al.
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Table 3 Factors guiding the choice when antibiotic pro-
phylaxis against infective endocarditis (IE) is optional.
Arguments for prescription Arguments against
prescription
Age >65 years
Cardiac, renal, respiratory or
hepatic failure, diabetes
(acquired [splenectomy],
constitutional or therapeutic
[corticosteroids,
immunosuppressors]),
immunodepression
Allergy to several
antibiotics
Patient’s opinion
after information
Buccodental state
Especially inadequate
buccodental hygiene
Procedure
Important bleeding (intensity,
duration)
Technically difﬁcult procedure
(prolonged procedure)
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Consequently, the working group made the following sug-
estions: to maintain the principle of antibiotic prophylaxis
hen performing at risk procedures in patients with at risk
eart diseases but to limit its use to cases in which the ratio
f individual beneﬁt to individual and collective risk is the
ighest.
The recommendations of the working group do not over-
ide the physician’s evaluation of individual risk for a given
atient.
eﬁnition of at risk groups
wo groups of patients are deﬁned: group A, high risk (high
ncidence and severity [morbidity, mortality] of IE) and
roup B, lesser risk (lesser incidence and severity of IE)
Table 1).
Compared with the global population, there is no
ncreased risk of IE with other cardiac conditions, i.e., atrial
eptal defect, pacemaker (but the implantation of the pace-
aker requires antibiotic prophylaxis), coronary angioplasty
ith or without implantation of an endoprosthesis, dilated
ardiomyopathy without signiﬁcant mitral regurgitation, iso-
ated mitral stenosis and minimal valvular regurgitation
etected only by Doppler echocardiography.
mportance of hygiene measures
eneral hygiene measures are of fundamental importance;
he aim is to decrease the risk of bacteraemia, whatever its
rigin, especially bacteraemia caused by bacteria that have
cardiac tropism. The hygiene measures include prevention
nd treatment of infectious foci: strict and permanent buc-
odental and cutaneous hygiene to prevent any rupture of
he cutaneous and mucosal barriers, disinfection of wounds,
urative antibiotic treatment of any infectious foci, strict
ompliance with asepsis when performing operations asso-
iated with a risk of infection, and eradication or decrease
f the bacterial inoculum in cases of chronic skin carriage
renal dialysis). The buccodental state must be surveyed sys-
ematically at least twice a year in patients with a heart
isease associated with an IE risk.
Any procedure that leads to a mucosal or cutaneous
ound must be prevented. Piercing is strictly contraindi-
ated in at risk patients. Acupuncture should be used only
fter informing the patient of the possible risk of IE and with
dequate clinical surveillance after the treatment. Infu-
ion catheters should be limited to cases in which they are
andatory, especially in at risk patients; they should be
eplaced systematically every 3—4 days, peripheral rather
han central catheters should be used, and the infusion nee-
le entry site should be surveyed closely.
uccodental procedures
n patients from groups A and B, a chlorhexidine mouth-
ash is recommended for 30 seconds before dental care and
uccodental care should be given in as few sessions as pos-
ible. If care requires several sessions, these must be at
east 10 days apart, if possible. Contraindicated procedures,
nd procedures for which antibiotic prophylaxis is recom-
ended, optional or not recommended, are presented in
able 2.
s
r
C
dPatient’s opinion after
information
In group B patients, antibiotic prophylaxis is optional;
he decision should be made by the physician managing the
atient, taking into account the nature of care and the
atient’s state. Factors for this choice are listed in Table 3.
hatever the choice, it must be made after informing the
atient and obtaining their consent to the offered strategy,
hich must be written down on a follow-up ﬁle given to
ach patient. The patient should know that if they expe-
ience fever or symptoms, especially in the month after
ental care, they must consult a physician as soon as possi-
le, before starting any antibiotic treatment, and inform the
hysician of the previous dental care so that blood cultures
an be done before initiating antibiotic treatment.
on-buccodental procedures
ontraindicated procedures, and procedures for which
ntibiotic prophylaxis is recommended, optional or not rec-
mmended, are presented in Table 4.
odalities of antibiotic prophylaxis
hese are given in Tables 5—7.
004: status quo for the ESC and the BCS
he 2004 ESC recommendations [7] cite the French rec-
mmendations issued in 1985 [13], but do not cite those
ublished in 2002, despite the existence of an English ver-
ion. The 2004 recommendations are similar to the previous
ecommendations.
The 2004 recommendations of the BCS and the Royal
ollege of Physicians [8,14,15] resemble the ESC recommen-
ations.
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Table 4 Non-buccodental procedures; French recommendations [3].
Antibiotic prophylaxis
Group A Group B
Ear, nose and throat procedures
Tonsillectomy and adenoidectomy Recommended Optional
Endoscopic surgery for chronic sinusitis Recommended Optional
Rigid bronchoscopy Recommended Optional
Flexible bronchoscopy Optional Not recommended
Nasal or oral intubationa Not recommended Not recommended
Nasal aspiration Not recommended Not recommended
Laryngeal mask Not recommended Not recommended
Percutaneous dilation of tracheostomy Not recommended Not recommended
Digestive procedures
Oesophageal dilation Recommended Recommended
Sclerotherapyb Recommended Recommended
Retrograde cholangiography Recommended in cases of
biliary obstruction or
pancreatic pseudocyst
Sphincterotomy
Elastic ligature of oesophageal varicesb Optional Not recommended
Colonoscopyc Optional Not recommended
Fine needle puncture guided by ultrasonography Not recommended Not recommended
Gastroscopy Not recommended Not recommended
Hepatic biopsy Not recommended Not recommended
Cardiac procedures
Transoesophageal ultrasonography Not recommended Not recommended
Intraaortic counterpulsation balloon Not recommended Not recommended
Percutaneous coronary angioplasty with or without endoprosthesis Not recommended Not recommended
Urological procedures
Transurethral prostatic resection, infected urine Contraindicated Contraindicated
Removal of a catheter inserted during an urological surgical
procedure, infected urine
Recommendedd Recommendedd
Transurethral prostatic resection, sterile urine Recommended Optional
Prostatic biopsye Recommended Optional
Urethral dilation Recommended Optional
Extracorporeal lithotripsy Optional Not recommended
Urethral catheterization Not recommended Not recommended
Cystoscopyf Not recommended Not recommended
Removal of a catheter inserted during an urological surgical
procedure, sterile urine
Not recommended Not recommended
Gyneco-obstetrical procedures
Intrauterine device Contraindicated Contraindicated
Low tract delivery Optionalg Not recommended
Caesarean sectionh Not recommended Not recommended
Cervical or endometrial biopsy Not recommended Not recommended
Curettage Not recommended Not recommended
Skin procedures
Instrumental treatment of furuncles Recommended Recommended
Excision of skin lesions ulcerative or not Optional Optional
a Except if intubation difﬁcult and/or traumatic, groupA.
b Except during emergency haemostatic treatment.
c Antibiotic prophylaxis possible after initiation of procedure if a neoplasm is discovered after biopsy, polypectomy or mucosectomy or
if examination is difﬁcult.
d The antibiotic is chosen according to results given by cytobacteriological examination of urine and antibiogram.
e Preceded systematically by rectal enema.
f Procedure contraindicated if urine infected, antibiotic prophylaxis if
g If amniotic membrane ruptures prematurely and labour starts 6 hour
h Follow recommendations of the French Society of Anesthesia and Intbiopsy, groupA.
s before admission.
ensive Care for the general population.
238 F. Delahaye et al.
Table 5 Antibiotic prophylaxis against IE in dental care and upper respiratory tract procedures; ambulatory care; French
recommendations [3].
Antibiotic Dosage and route of administration
Single intake in the hour before the procedure
No allergy to beta-lactams Amoxicillin 3 g orallya
Allergy to beta-lactams Pristinamycin 1 g orally
Clindamycinb 600mg orally
a 2 g orally if the patient’s weight is less than 60 kg; paediatric oral dosage; amoxicillin 75mg/kg; pristinamycin 25mg/kg; clindamycin
15mg/kg.
b The respective percentage of streptococci strains with a decreased susceptibility to these 2 antibiotics must be taken into account
when making the choice.
Table 6 Antibiotic prophylaxis against infective endocarditis in dental care and upper respiratory tract procedures;
general anaesthesia; French recommendations [3].
Antibiotic Dosage and route of administration
Before (in the hour before the procedure) After (6 hours later)
No allergy to beta-lactams Amoxicillin 2 g intravenously (30minutes infusion) 1 g orally
Allergy to beta-lactams Vancomycin 1 g intravenously (≥60minutes infusion) No second dose
Teicoplanine 400mg intravenously (bolus) No second dose
Paediatric dose, amoxicillin 50mg/kg intravenously in the hour before the procedure and 25mg/kg orally 6 hours later; vancomycin
ylaxis
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o20mg/kg (maximum 1g); no ofﬁcial approval for antibiotic proph
006: major change to the BSAC
ecommendations
he 2006 BSAC recommendations [9] are similar to the
rench recommendations. The working group reiterates that
here is no proof of the efﬁcacy of antibiotic prophylaxis
ut takes into account the fact that clinicians would be
eluctant to accept a recommendation for not providing pro-
hylaxis. The British limit antibiotic prophylaxis to patients
ho are at particularly high risk for IE (French group A). As
n the French recommendations, there are tables listing the
Table 7 Antibiotic prophylaxis against infective endocarditis
mendations [3].
Antibiotic Dosage
Before
No allergy to beta-lactams Amoxicillin then
gentamycin
2 g intra
1.5mg/
infusion
Allergy to beta-lactams Vancomycin or
teicoplanine then
gentamycin
1 g intra
400mg
1.5mg/
infusion
Paediatric dose, amoxicillin 50mg/kg intravenously in the hour befor
2mg/kg (maximum 80mg); vancomycin 20mg/kg (maximum 1g); no
children.with teicoplanine in children.
rocedures and detailing whether antibiotic prophylaxis is
ecommended or not.
The working group adds an appendix for patients, which
entists may use when they explain the changes to the rec-
mmendations:Prevention of Infective Endocarditis Guidelines Informa-
tion for Patients and Parents. A BSAC group of experts
has spent a lot of time carefully looking at whether
dental treatment procedures are a possible cause of
IE [sometimes called bacterial endocarditis], which is
during urological and digestive procedures; French recom-
and route of administration
(in the hour before the procedure) After (6 hours later)
venously (30minutes infusion) 1 g orally
kg intravenously (30minutes
) or intramuscularly
No second dose
venously (≥60minutes infusion) No second dose
intravenously (bolus) No second dose
kg intravenously (30minutes
) or intramuscularly
No second dose
e the procedure then 25mg/kg orally 6 hours later; gentamycin
ofﬁcial approval for antibiotic prophylaxis with teicoplanine in
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tRecommendations on infective endocarditis prophylaxis
infection of the heart valve. After a very detailed anal-
ysis of all the available evidence they have concluded
that there is no evidence that dental treatment proce-
dures increase the risk of these infections. Therefore
it is recommended that the current practice of giving
patients antibiotics before dental treatment be stopped
for all patients with cardiac abnormalities, except for
those who have a history of healed IE, prosthetic heart
valves and surgically constructed conduits. The main rea-
sons for this are the lack of any supporting evidence that
dental treatment leads to IE and the increasing worry
that administration of antibiotics may lead to other seri-
ous complications such as anaphylaxis (severe allergy) or
antibiotic resistance. The advice from the BSAC is that
patients should concentrate on achieving and keeping a
high standard of oral and dental health, as this does
reduce the risk of endocarditis. Help for this will be
provided by your Dental Professional. BSAC, 2 February
2006.
An editorial presented these recommendations as a ‘rad-
ical step’ [16] and there have been diametrically opposed
views [17—20], with the risk of lack of understanding by
practitioners and patients being stressed [21]. The British
Congenital Cardiac Association and the BCS indicated their
displeasure [18]. For all these reasons, NICE was peti-
tioned to help to resolve ‘the current situation’ (see below)
[16,18,22].
2007: major change to the American
recommendations
The recommendations of the AHA cite the French and BSAC
recommendations and are endorsed by the American Dental
Association, the Infectious Diseases Society of America and
the Pediatric Infectious Diseases Society [10].
These recommendations are the 10th version to be issued
by the AHA. The 1st version was published in 1955 [2]. The
fundamental underlying principles that drove the formula-
tion of the AHA guidelines and the 9 previous AHA documents
were as follows: IE is an uncommon but life-threatening
disease and prevention is preferable to treatment of
established infection; certain underlying cardiac conditions
predispose to IE; bacteraemia with organisms known to
cause IE occurs usually in association with invasive dental,
gastrointestinal or genitourinary tract procedures; antimi-
crobial prophylaxis is proven to be effective for prevention
of experimental IE in animals; antimicrobial prophylaxis is
thought to be effective in humans for prevention of IE asso-
ciated with dental, gastrointestinal or genitourinary tract
procedures.
The 2007 working group believes that the ﬁrst
4 underlying principles are valid and have not changed in
the past 30 years, but that the validity of the ﬁfth principle
must be questioned.The primary reasons for the revision of the IE prophylaxis
guidelines are as follows:
• IE is much more likely to result from frequent exposure to
random bacteraemia associated with daily activities than
from bacteraemia caused by a dental, gastrointestinal
s
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tract or genitourinary tract procedure; prophylaxis may
prevent an exceedingly small number of cases of IE, if
any, in individuals who undergo a dental, gastrointestinal
tract or genitourinary tract procedure;
the risk of antibiotic-associated adverse events exceeds
the beneﬁt, if any, of prophylactic antibiotic therapy;
maintenance of optimal oral health and hygiene may
reduce the incidence of bacteraemia from daily activi-
ties and is more important than prophylactic antibiotics
for a dental procedure to reduce the risk of IE.
ationale for and against IE prophylaxis
ost published studies have focused on dental procedures
s a cause of IE.
requency, nature, magnitude and duration of
acteraemia associated with a dental procedure
ransient bacteraemia occurs frequently with manipulation
f the teeth and periodontal tissues, but there is a wide
ariation in the frequency of bacteraemia resulting from
ental procedures. Transient bacteraemia also occurs fre-
uently during routine daily activities unrelated to dental
rocedures, such as brushing teeth and chewing food. The
requency of bacteraemia from routine daily activities is far
reater than that associated with a dental procedure.
There are more than 700 species of bacteria in the mouth.
pproximately 30% of the ﬂora are streptococci, predomi-
antly of the viridans group.
The magnitude of bacteraemia resulting from a dental
rocedure is relatively low (<104 colony-forming units of
acteria per milliliter), similar to that resulting from rou-
ine daily activities, and is less than that used to cause
xperimental IE in animals (106—108 colony-forming units of
acteria per milliliter). Although the infective dose required
o cause IE in humans is unknown, the number of microorgan-
sms present in blood after a dental procedure or associated
ith daily activities is low. Cases of IE caused by oral bacte-
ia probably result from exposure to low inocula of bacteria
n the bloodstream that result from routine daily activities
nd not from a dental procedure. Additionally, most patients
ith IE have not had a dental procedure within the 2weeks
efore the onset of symptoms of IE.
There may not be a clinically signiﬁcant difference in
he frequency, nature, magnitude and duration of bacter-
emia associated with a dental procedure compared with
he frequency, nature, magnitude and duration of bacter-
emia resulting from routine daily activities.
mpact of dental disease, oral hygiene and type of
ental procedure on bacteraemia
t is assumed that a relationship exists between poor oral
ygiene, the extent of dental and periodontal disease, the
ype of dental procedure, and the frequency, nature, mag-
itude and duration of bacteraemia, but the presumed rela-
ionship is controversial. Nevertheless, available evidence
upports an emphasis on maintaining good oral hygiene and
radicating dental disease to decrease the frequency of bac-
eraemia from routine daily activities. Tooth extraction is
hought to be the dental procedure most likely to cause bac-
eraemia. However, numerous other dental procedures have
2 F. Delahaye et al.
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It is likely that the number of cases of IE that result
from a dental procedure is exceedingly small. Therefore
the number of cases that could be prevented by antibiotic
prophylaxis, even if 100% effective, is similarly small.
Cardiac diseases and IE
The American working group considered 3 distinct issues:
• the underlying cardiac conditions that have the highest
predisposition to the acquisition of IE over a lifetime;
• the underlying cardiac conditions associated with the
highest risk of adverse outcome from IE;
• whether the recommendations for IE prophylaxis should
be based on either or both of these two conditions.
For 3 cardiac conditions—prosthetic cardiac valve, previ-
ous IE and cyanotic CHD (Table 8)—both risk of IE and risk of
adverse outcome from IE are increased. Antibiotic prophy-
laxis is recommended before dental care in patients with
these cardiac conditions. There are no more recommenda-
tions for other patients (French group B), in whom risk of IE
is increased but the risk of adverse outcome is not increased.
Antibiotic prophylaxis
An antibiotic for prophylaxis should be administered in a
single dose before the procedure. If, inadvertently, the
antibiotic is not administered before the procedure, it may
be administered up to 2 hours after the procedure.
Dental procedures for which IE prophylaxis is reasonable
are all dental procedures that involve manipulation of gingi-
val tissue or the periapical region of teeth or perforation of
the oral mucosa. The recommended antibiotic is amoxicillin,
2 g, 30 to 60minutes before the dental care. If the oral route
cannot be used, ampicillin, cefazolin or ceftriaxone can be
Table 8 Cardiac conditions associated with the highest
risk of adverse outcome from endocarditis for which pro-
phylaxis with dental procedures is reasonable; American
recommendations [10].
Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair
Previous infective endocarditis
CHDa
Unrepaired cyanotic CHD, including palliative shunts
and conduits
Congenital heart defect completely repaired with
prosthetic material or device, whether placed by
surgery or by catheter intervention, during the ﬁrst
6months after the procedureb
Repaired CHD with residual defects at the site or
adjacent to the site of a prosthetic patch or
prosthetic device (which inhibit endothelialization)
Cardiac transplantation recipients who develop cardiac
valvulopathy
CHD: congenital heart disease.40
een reported to be associated with a risk of bacteraemia
hat is similar to that resulting from tooth extraction.
mpact of antibiotics on bacteraemia from a dental
rocedure
he ability of antibiotic therapy to prevent or reduce the
requency, magnitude or duration of bacteraemia associ-
ted with a dental procedure is controversial. Some studies
eported that antibiotics administered before a dental pro-
edure reduced the frequency, nature and/or duration of
acteraemia, whereas others did not.
umulative risk over time of bacteraemia from
outine daily activities compared with from a
ental procedure
untheroth estimated a cumulative exposure to bacter-
emia of 5370minutes over a 1-month period resulting from
andom bacteraemia from chewing food and oral hygiene
easures, such as brushing teeth [23]. Roberts estimated
hat brushing teeth twice daily for 1 year had a 154,000
imes greater risk of exposure to bacteraemia than that
esulting from a single tooth extraction [24]. The cumula-
ive exposure to bacteraemia from routine daily activities
uring 1 year may be as high as 5.6million times greater
han that resulting from a single tooth extraction [24].
esults of clinical studies of prophylaxis against IE
or dental procedures
prospective randomized trial has not been done. Data from
ase-control studies are limited by the low incidence of IE,
he wide variation in the types and severity of underlying
ardiac conditions, and the large variety of invasive den-
al procedures and dental disease states [25—29]. In the
tudies by van der Meer et al., dental and other procedures
aused only a small fraction of cases of IE and prophylaxis
ould prevent only a small number of cases even if it were
00% effective [28,29]. Strom et al. concluded that dental
reatment was not a risk factor for IE even in patients with
alvular heart disease [27]. In a recent French study, the risk
f IE from a dental procedure was estimated at 1 in 46,000,
alling to 1 in 150,000 with prior antibiotic treatment. The
uthors conclude that ‘a huge number of prophylaxis doses
ould be necessary to prevent a very low number of cases’
30].
bsolute risk of IE resulting from a dental
rocedure
f dental treatment causes 1% of all cases of viridans group
treptococcal IE annually, the overall risk in the general
opulation is estimated to be as low as one case of IE per
4million dental procedures. The estimated absolute risk
ates for IE from a dental procedure in patients with under-
ying cardiac conditions are as follows:mitral valve prolapse, 1 per 1.1million procedures;
congenital heart disease (CHD), 1 per 475,000 procedures;
presence of a prosthetic cardiac valve, 1 per 114,000 pro-
cedures;
previous IE, 1 per 95,000 procedures.
a Other than for the conditions listed above, antibiotic prophy-
laxis is no longer recommended for any other form of CHD.
b Prophylaxis is reasonable because endothelialization of pros-
thetic material occurs within 6months after the procedure.
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Table 9 Comparison of the American 2006 valvular heart disease guidelines [32] and the 2008 focused update of section
2.3.1. (endocarditis prophylaxis) [31].
2006 recommendations 2008 recommendations Comments
Class I Class IIa Modiﬁed
recommendation (class
of recommendation
changed from I to IIa,
changed text)
Prophylaxis against IE is
recommended for the
following patients
(level of evidence: C)
Patients with
prosthetic heart
valves and patients
with a history of IE
Patients who have
complex cyanotic CHD
(e.g., single-ventricle
states, transposition
of the great arteries,
tetralogy of Fallot)
Patients with
surgically-constructed
systemic pulmonary
shunts or conduits
Patients with
congenital cardiac
valve malformations,
particularly those
with bicuspid aortic
valves, and patients
with acquired valvular
dysfunction (e.g.,
rheumatic heart
disease)
Patients who have
undergone valve
repair
Patients who have
hypertrophic
cardiomyopathy when
there is latent or
resting obstruction
Patients with mitral
valve prolapse and
auscultatory evidence
of mitral regurgitation
and/or thickened
leaﬂets on
echocardiographya
Prophylaxis against IE is
reasonable for the
following patients at
highest risk of adverse
outcomes from IE
because of dental
procedures that involve
manipulation of either
gingival tissue or the
periapical region of
teeth or perforation of
the oral mucosa
Patients with prosthetic
cardiac valves or
prosthetic material used
for cardiac valve repair
(level of evidence: B)
Patients with previous
IE (level of evidence: B)
Patients with CHD (level
of evidence: B)
Unrepaired cyanotic
CHD, including
palliative shunts and
conduits
Completely repaired
congenital heart defect
repaired with prosthetic
material or device,
whether placed by
surgery or by catheter
intervention, during the
ﬁrst 6months after the
procedure
Repaired CHD with
residual defects at the
site or adjacent to the
site of a prosthetic
patch or prosthetic
device (both of which
inhibit
endothelialization)
Cardiac transplant
recipients with valve
regurgitation due to a
structurally abnormal
valve (level of
evidence: C)
There are no Class I
recommendations for IE
prophylaxis
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Table 9 (Suite )
2006 recommendations 2008 recommendations Comments
Class III Class III Modiﬁed recommendation
(changed text)
Prophylaxis against IE is not
recommended for the
following patients (level of
evidence: C)
Patients with isolated
secundum atrial septal defect
Patients≥ 6months after
successful surgical or
percutaneous repair of atrial
septal defect, ventricular
septal defect, or patent
ductus arteriosus
Patients with mitral valve
prolapse without regurgitation
or thickened leaﬂets on
echocardiographya
Patients with physiological,
functional or innocent heart
murmurs, including patients
with aortic valve sclerosis
deﬁned by focal areas of
increased echogenicity and
thickening of the leaﬂets
without restriction of motion
and a peak velocity < 2.0m/s
Patients with
echocardiographic evidence of
physiologic mitral
regurgitation in the absence
of a murmur and with
structurally normal valves
Patients with
echocardiographic evidence of
physiological tricuspid
regurgitation and/or
pulmonary regurgitation in the
absence of a murmur and with
structurally normal valves
Prophylaxis against IE is not
recommended for non-dental
procedures (such as
transoesophageal
echocardiogram,
oesophagogastroduodenoscopy,
or colonoscopy) in the absence
of active infection (level of
evidence: B)
IE: infective endocarditis; CHD: congenital heart disease.
a Patients with mitral valve prolapse without regurgitation require additional clinical judgment. Indications for antibiotic prophylaxis in
mitral valve prolapse are discussed in Section 3.5.2. Patients who do not have mitral regurgitation but who do have echocardiographic
evidence of thickening and/or redundancy of the valve leaﬂets, and especially men ≥45 years of age, may be at increased risk for IE.
Additionally, approximately one third of patients with mitral valve prolapse without mitral regurgitation at rest may have exercise-
induced mitral regurgitation. Some patients may exhibit mitral regurgitation at rest on one occasion and not on another. There are no
data available to address this latter issue, and at present, the decision must be left to clinical judgment, taking into account the nature
of the invasive procedure, the previous history of endocarditis, and the presence or absence of valve thickening and/or redundancy.
Class I: beneﬁt »> risk; procedure/treatment SHOULD be performed/administered.
Class IIa: beneﬁt » risk; additional studies with focused objectives needed; IT IS REASONABLE to perform procedure/administer treatment.
Class III: risk ≥ beneﬁt; procedure/treatment should NOT be performed/administered AS IT IS NOT HELPFUL AND MAY BE HARMFUL.
Level of evidence B: limited populations evaluated; data derived from a single randomized trial or non-randomized studies.
Level of evidence C: very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.
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Table 10 Summary of current international guidelines [33].
French recommendations 2002 [3] BSAC 2006 [9] AHA 2007 [10] NICE 2008 [11]
High-risk patients Previous IE
Prosthetic valve
Non-operated cyanotic CHD and surgical
bypass (pulmonary-systemic)
Previous IE
Prosthetic valve
Prosthetic systemic or
pulmonary shunt or
conduit
Previous IE
Prosthetic valve
Unrepaired or incompletely
repaired cyanotic CHD
CHD repaired with prosthetic
material (for 6months after
the procedure)
Valve disease in recipients of
a cardiac transplant
Previous IE
Prosthetic valve
Acquired valvular heart
disease with stenosis or
regurgitation
Structural CHD, including
surgically corrected or
palliated structural
conditions, but excluding
isolated atrial septal defect,
fully repaired ventricular
septal defect or fully
repaired patent ductus
arteriosus, and closure
devices that are judged to be
endothelialized
Hypertrophic cardiomyopathy
Lower-risk patients Other valve disease (including mitral
valve prolapse with mitral insufﬁciency
or valve thickening)
Non-cyanotic CHD (except atrial septal
defect)
Hypertrophic obstructive cardiomyopathy
Procedures requiring
prophylaxis in high-risk
patients
All invasive dental, respiratory,
gastrointestinal and genitourinary
procedures
All invasive dental,
respiratory,
gastrointestinal and
genitourinary
procedures
Dental procedures involving
manipulation of gingival
tissue, the periapical region
of teeth or perforation of the
oral mucosa
Invasive procedures of the
respiratory tract needing
incision or biopsy of the
respiratory mucosa
Gastrointestinal and
genitourinary procedures at a
site where there is suspected
preexisting infection
Procedures requiring
prophylaxis in lower-risk
patients
Optional, based on composite clinical
assessment of the patient and procedural
risk
Post hoc prophylaxis can be given in the
event of unexpected procedural
complexity
IE: infective endocarditis; CHD: congenital heart disease.
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sed. For individuals who are allergic to penicillins or amox-
cillin, the use of cephalexin or another ﬁrst-generation oral
ephalosporin, clindamycin, azithromycin or clarithromycin
s recommended.
Antibiotic prophylaxis is reasonable before an invasive
rocedure of the respiratory tract that involves incision or
iopsy of the respiratory mucosa, such as tonsillectomy and
denoidectomy. Antibiotic prophylaxis is not recommended
or bronchoscopy unless the procedure involves incision of
he respiratory tract mucosa.
The administration of prophylactic antibiotics solely
o prevent IE is not recommended for patients who
ndergo genitourinary or gastrointestinal tract procedures,
ncluding diagnostic oesophagogastroduodenoscopy or
olonoscopy.
In August 2008, the American College of Cardiology (ACC)
nd the AHA published a ‘focused update’ on IE prophy-
axis [31]. Previously, the writing of recommendations could
ast 3 years. Since 2006, the ACC and the AHA have settled
faster update procedure. New data are reviewed twice
year. However, the text does not cite the recommenda-
ions by NICE that were published in April 2008. Differences
etween the 2006 recommendations on valvular heart dis-
ase [32] and the 2007 recommendations on prevention of
E [10] are presented in Table 9.
008: major change to the British
ecommendations
ery recently, NICE, an independent organization in charge
f issuing recommendations on health, published recom-
endations on the prevention of IE [11]:
Antibiotic prophylaxis against IE is not recommended
in the following circumstances: for patients undergoing
dental procedures; for patients undergoing non-dental
procedures at the upper and lower gastrointestinal tract,
at the genitourinary tract (this includes urological,
gynaecological and obstetric procedures, and childbirth)
or at the upper and lower respiratory tract (this includes
ear, nose and throat procedures, and bronchoscopy).
Chlorhexidine mouthwash should not be offered as pro-
phylaxis against IE to people at risk of IE who are having
dental procedures.
The main differences between the 4 recommendation
exts [3,9—11] are presented in Table 10 [33]. With these
ast recommendations, ‘the loop is looped’ in 2002, the
rench proposed that antibiotic prophylaxis before a pro-
edure should be optional in patients at risk but not at very
igh risk of IE (group B). Whereas the ESC and the BCS did not
hange their previous recommendations in 2004, the British
nfectious disease specialists went a step further than the
rench in 2006, i.e., no more prophylaxis in group B patients.
n additional step was taken by the ACC and the AHA in 2007,
.e. no more prophylaxis before genitourinary or gastroin-
estinal procedures in groupA patients. The ﬁnal step was
aken by NICE in 2008, i.e. no antibiotic prophylaxis at all!
There already are indignant reactions in the literature
nd the debate is just beginning. However, it must be
tressed that all these recommendation texts are based on
[
[F. Delahaye et al.
ery complete and thorough literature reviews. The recom-
endation not to give any antibiotic prophylaxis against IE
n patients at risk for IE is not absurd as there is no proof of
ts efﬁcacy.
The ESC is revising its recommendations on IE and the
ew recommendations are expected in 2009. The French
ociety of Cardiology, the French Society of Infectious Dis-
ases (SPILF: Société de pathologie infectieuse de langue
ranc¸aise) and other societies concerned by IE will then have
o endorse or not endorse these recommendations.
Until then, what to do? The French recommendations do
ot differ greatly from the American and the 2006 British
ecommendations. Perhaps the 2008 NICE guidance goes too
ar. We would advise adhering to our 2002 guidelines while
aiting for the French revised guidelines, which will be pub-
ished in 2009 or 2010.
The different countries must monitor the incidence of IE
n order to detect any increase and must verify whether an
ncrease is due to less use of antibiotic prophylaxis, as some
alifornian investigators did recently in a very preliminary
tudy [34].
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